drugset / Trial / NCT00996281

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

NCT00996281

Phase 3 Completed 837 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.

Timeline

Start
2009-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Chlorthalidone Other / unclassified 12.5 mg Oral
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral
Comparator Olmesartan medoxomil Unknown 20 mg Oral